



PATENT
SPC 7025

MAR 1 1987
U.S. PAT. & TM. OFF.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EDWARD DAVISON ET AL. : EXAMINER: D. BJORKMAN
SERIAL NO.: .07/030,658 : ART UNIT: 121
FILED: MARCH 25, 1987 :
FOR: PHARMACEUTICALLY
ACCEPTABLE SALTS :

Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

6/12
EBW
3-26-88
I hereby certify that this
correspondence is being
deposited with the United States
Postal Service as First Class mail
in an envelope addressed to:
Commissioner of Patents and
Trademarks, Washington, D.C.
20231, on the 2nd day of
March, 1988.
By *[Signature]*

In response to the Official Action of October 6, 1987, the three (3) month shortened statutory period set for response thereto having been extended two (2) months by the accompanying request, is now set to expire on March 6, 1988.

In the Action of October 6, 1987 the Examiner rejected Claims 1-11 under 35 U.S.C. 112, second paragraph, as the composition claims had not recited an amount of active ingredient used, claim 12 under 35 U.S.C. 101, as the product claim was drafted in terms of use and claims 1-12 under 35 U.S.C. 103 as being unpatentable over Campbell, et al. (U.S. 4,572,909) in view of Schmidt, et al. (U.S. 3,816,612) or Spiegel, et al. (U.S. 4,032,637).

IN THE CLAIMS

Please amend the claims as follows:

2. (Amended). A pharmaceutical composition comprising an antihypertensive, antiischaemic or angina - alleviating effective amount of the besylate salt of amlodipine as claimed in claim 1 together with a pharmaceutically acceptable diluent

or carrier.

16-1445 010 116 170.00CH

3. (Amended). A tablet formulation comprising an antihypertensive, antiischaemic or angina - alleviating effective amount of the besylate salt of amlodipine as claimed in claim 1 in admixture with excipients.

P0093832

P0093832